A recent trial showed that nicotinamide riboside supplementation might reduce airway inflammation in patients with COPD who ...

Objective: To investigate the efficacy and tolerability of high-dose N-acetylcysteine (NAC) in the treatment of patients with exacerbations of chronic obstructive pulmonary disease (COPD).

If symptoms are no longer controlled or if inhaled, short-acting beta2-agonist is less effective, then re-evaluate the patient and COPD treatment regimen. Do not exceed the recommended dose of ...

Tezepelumab did not significantly decrease moderate or severe COPD exacerbations compared with placebo, the COURSE trial found.

DOI: 10.1136/bmj-2024-080409 Meng-Ting Wang et al, Environmentally friendly inhaler regimens for COPD, BMJ (2024). DOI: 10.1136/bmj.q2825 ...

If these trials confirm the findings, benralizumab could become the first new therapy approved for eosinophilic exacerbations ...

Black Americans have a higher likelihood of having asthma-COPD overlap syndrome (ACOS) but may not know it. Here’s what you ...

And according to the WHO, COPD is the fourth leading cause of death worldwide ... “WIN378, with its best-in-class potential to provide effective treatment through a six-month dosing regimen, could ...